A vaccine administered during pregnancy is substantially lowering hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a decrease of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and passing protection through the placenta. A major new study analysing nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the period when infants are particularly susceptible to the virus. RSV affects roughly 50 per cent of newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.
How the vaccine safeguards vulnerable infants
RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects approximately half of all newborns in their first few months of life. The virus can range from causing mild cold-like symptoms to triggering severe chest infections that cause babies to struggle to breathe and feed. In the most serious cases, the inflammation in the lungs becomes life-threatening, with small numbers of infants dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of severe RSV infections: “In babies with bad infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening with good reason.”
The pregnancy vaccine works by activating the mother’s immune system to generate protective antibodies, which are then passed to the foetus through the placenta. This mother-derived protection provides newborns with instant defence from the moment of birth, precisely when they are highly susceptible to RSV. The latest research shows that protection reaches approximately 85% when the vaccine is given four weeks or more before delivery. Even briefer gaps between vaccination and birth can still provide substantial defence, with evidence indicating that a two-week gap is sufficient to shield babies delivered prematurely. Dr Watson recommends pregnant women to have the vaccine at the recommended time, whilst noting that protection remains possible even if administered later in the third trimester.
- Nearly 85 per cent protection when vaccinated 4 weeks before birth
- Antibodies from the mother transferred through placenta protect newborns from day one
- Coverage achievable with two-week gap before premature birth
- Vaccination during third trimester still provides significant infant protection
Compelling evidence from the latest research
The performance of the pregnancy RSV vaccine has been established through a thorough investigation undertaken in England, reviewing data from close to 300,000 babies born between September 2024 and March 2025. This constitutes approximately 90% of all births during that half-year window, providing robust and representative information of the vaccine’s practical effectiveness. The study’s results have been endorsed by the UK Health Security Agency as showing “excellent protection” for newborns during their earliest and most vulnerable period. The scale of this research offers healthcare professionals and prospective parents with assurance in the vaccine’s proven efficacy across varied populations and settings.
The results reveal a notable picture of the vaccine’s protective power. More than 4,500 babies were admitted to hospital with RSV during the study period, with the vast majority being infants whose mothers had not been given the vaccination. This marked difference underscores the vaccine’s vital importance in reducing the risk of serious illness in newborns. The reduction in hospital admissions above 80 per cent represents a major public health success, possibly preventing thousands of infants from experiencing the alarming and potentially severe symptoms associated with severe RSV infection. These findings support the importance of the vaccination programme established in the UK in 2024.
Research approach and coverage
The research examined birth and hospital admission records from England over a six-month timeframe, capturing data on approximately 90 per cent of all births during this timeframe. By examining nearly 300,000 babies born to vaccinated and unvaccinated mothers, researchers were able to identify clear comparisons of RSV infection rates and hospital admissions. The large sample size and thorough nature of the data collection ensured that findings were statistically robust and reflective of the wider population, rather than isolated cases or limited subgroups.
The study specifically tracked hospital admissions for RSV among infants born to mothers who had been given the vaccine at varying intervals before delivery. This allowed researchers to determine the minimum time required between vaccination and birth for best possible protection, as well as to determine whether protection remained meaningful with reduced timeperiods. The methodology measured practical outcomes rather than controlled laboratory conditions, providing tangible evidence of how the vaccine performs when administered across different clinical contexts and patient circumstances throughout the final three months of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Learning about RSV and the risks
Respiratory syncytial virus, commonly referred to as RSV, is among the primary causes of hospital admission in infants aged under twelve months across the United Kingdom. The virus affects approximately half of all newborns during their early months of life, with severity varying dramatically from minor cold-type symptoms to severe, life-threatening chest infections. More than 20,000 babies require serious hospital treatment for RSV annually in the UK alone, placing enormous strain on children’s wards and newborn care units during peak seasons.
The infection causes inflammation deep within the lungs and airways, making it perilously hard for affected infants to feed and breathe properly. Parents commonly see their babies struggling visibly, their chests heaving as they try to pull enough air into their weakened respiratory system. Whilst most newborns improve through clinical support, a limited though important group succumb from RSV-related complications yearly, making prevention through vaccination a critical public health imperative for defending the youngest and most at-risk members of society.
- RSV produces inflammation in lungs, leading to severe breathing difficulties in infants
- Nearly 50% of newborns acquire the infection during their first few months alive
- Symptoms range from minor cold-like symptoms to serious chest infections that threaten life requiring hospitalisation
- More than 20,000 UK babies require serious hospital care for RSV annually
- A small number of babies succumb to RSV complications each year in the UK
Adoption rates and expert recommendations
Since the RSV vaccine programme launched in 2024, health officials have highlighted the importance of pregnant women getting their jab at the best time for maximum protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has underscored that timing matters greatly for ensuring newborns receive the most robust immunity from birth. Whilst the evidence indicates that vaccination at least four weeks before delivery offers nearly 85% protection, experts advise women to get their vaccine as early as possible from 28 weeks of pregnancy forward to enhance the antibodies passed to their babies through the placenta.
The communication from public health bodies remains clear: pregnant women should prioritise getting vaccinated during their final three months, even if circumstances mean they cannot get vaccinated at the optimal time. Dr Watson has provided reassurance to expectant mothers that protection is still achievable with reduced timeframes between vaccination and birth, including even a two-week gap for those delivering slightly early. This adaptable strategy recognises the realities of pregnancy and childbirth whilst ensuring strong safeguarding for vulnerable newborns during their most critical early months when RSV poses the greatest risk of serious illness.
Regional differences in vaccine uptake
Whilst the RSV vaccine programme has been implemented across England, uptake rates and implementation timelines have varied across different regions and NHS trusts. Some areas have attained higher vaccination coverage among qualifying expectant mothers, whilst others remain focused to boost understanding and availability of the jab. These regional differences reflect differences across healthcare infrastructure, engagement approaches, and local engagement efforts, though the overall statistics demonstrates robust and reliable protection irrespective of geographical location.
- NHS trusts deploying diverse outreach initiatives to engage with pregnant women
- Regional disparities in vaccine uptake rates throughout England require targeted improvement
- Community health services adapting programmes to align with local requirements and situations
Practical implications and parent viewpoints
The vaccine’s remarkable effectiveness provides tangible benefits for families throughout the United Kingdom. With over 20,000 babies hospitalised annually due to RSV before the rollout of this protective measure, the 80% reduction in admissions equates to thousands of infants shielded from severe infection. Parents no more face the troubling prospect of seeing their babies labour to breathe or labour to feed, symptoms that characterise severe RSV infections. The vaccine has substantially transformed the terrain of neonatal breathing health, offering expectant mothers a active means to safeguard their most vulnerable children during those crucial first weeks.
For families like that of Malachi, whose serious RSV infection led to profound brain damage, the vaccine’s accessibility carries significant emotional significance. His mother’s promotion of the jab emphasises the profound consequences that treatable infection can inflict on young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story strikes a chord with parents now provided with protection. The knowledge that such grave complications—hospitalisation, oxygen dependency, neurological damage—are now mostly preventable has provided considerable reassurance to expectant mothers in their final trimester, converting what was once an unavoidable seasonal threat into a manageable health risk.